It is interesting to note that a previous study in human HCM detected CD36 deficiency in symptomatic patients, while asymptomatic HCM (i.e., without cardiac hypertrophy and HCM-related mutations) had normal CD36 levels [73], suggesting that changes in CD36 availability associate with the metabolic shift of FAs towards glucose consumption. Here, CD36 is linked to cardiac hypertrophy.